Finland’s leading economy media tells about the Oscare innovation used in pharmacy

Kauppalehti, Finland’s leading economy media tells in its latest issue about Oscare Medical’s innovation. OsCare Sono™ enables the easy and reliable measurement of bone strength, providing information on the risk of osteoporosis.

The article features the new health and wellness concept of pharmacy Ympyrätalon apteekki in Helsinki. Pharmacist Tiina Vaitomaa tells that there is a separate space in the pharmacy, where a nurse measures bone strength with OsCare Sono™, cholesterol, blood pressure as well as makes intraocular pressure measurements with iCare. Pharmacist Vaitomaa sees that pharmacies can have a role in the prevention of diseases and in counceling. She tells that if abnormal measurements results are seen, the patient is advised to consult a physician.

Kauppalehti also interviewed Harri Sievänen, who is the research director in the Centre for Health Promotion Research in Finland and the president of Luustoliitto, the national health organization promoting bone health. Dr. Sievänen tells that OsCare Sono™ measurement results correlate with cortical thickness and porosity of the bone, which are important factors in defining bone strength.

One out of three women over 50 will experience osteoporotic fractures, as will one out of five men. Postmenopausal women are at a higher risk for osteoporosis due to decreasing estrogen levels. Also certain diseases such as the celiac disease, or certain treatments such as the cortisone treatment affect the bones. Harri Sievänen reminds that bones should get enough load through sports  in childhood and adolescence – this is one of the best means to prevent osteoporosis.

http://www.businessopas.fi/innovaatiot/kovaa-luuta (the article is in Finnish)

OsCare Sono™ provides information on bone quality in health checks in Finland

A Finnish company providing screening type of health assessments, Suomen Osteomittaus, has purchased OsCare Sono™ for performing bone health checks. Suomen Osteomittaus provides health checks for bones and vasculature in health fair type of events and in enterprises all around Finland. With OsCare Sono™, the customers of Suomen Osteomittaus can benefit of a quick and comfortable check up of their bone strength, providing information on osteoporosis and future fracture risk. www.osteomittaus.fi

Mervi Turunen appointed Sales and Marketing Manager for Oscare Medical

Mervi Turunen has started as the Sales and Marketing Manager for Oscare Medical. Mervi brings 14 years of experience in global marketing management, portfolio planning and R&D for medical technology. In Instrumentarium and GE Healthcare she managed the clinical networking and connectivity products and held roles in international marketing, product integration planning across business units, M&A integration and managing the establishment of sourcing relationships. In Nexstim she was responsible for the global marketing of a unique transcranial magnetic stimulation device targeted for brain mapping prior to neurosurgery and for neuromodulation in stroke and depression. She has also worked for two years in the Hospital district of Helsinki and Uusimaa, being responsible for customer relations in the Medical imaging center.

OsCare Sono™ portrayed in the Finnish Design Yearbook

OsCare Sono™ is not only accurate and easy to use, it is also pleasing to the eye. OsCare Sono™ was recently selected to be displayed in the Finnish Design Yearbook. The Finnish Design Yearbook is the internationally most recognized review of Finnish contemporary design. It is published now for the fifth time funded by Design Forum Finland. The earlier yearbooks have spread the message of Finnish design to more than 40 countries. The OsCare Sono™ design was created in Aivan, www.aivan.fi.

See more at:

http://www.designforum.fi/communications/finnish_design_yearbook

Revenio Group has acquired the majority of Oscare Medical Oy

Revenio Group Corporation has increased its ownership in Oscare Medical Oy to 53% on December 4, 2013. Owning the majority of Oscare Medical fits Revenio’s strategic objective to expand their health technology segment. The objective is to offer health care professionals an even more extensive product range.

Osteoporosis is often only discovered after the first fracture, which is typically suffered in the wrist, hip, or vertebrae. In 2010, 22 million women and 5.5 million men were estimated to have osteoporosis in the EU and 3.5 million new fragility fractures were sustained. Osteoporosis accounted for more disability and life years lost than rheumatoid arthritis. Osteoporosis screening can be performed quickly and cost-efficiently using the OsCare Sono™ osteoporosis detection device.

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy. The widely patented Icare product family is the current cornerstone of the Group’s success. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. The Revenio Group also includes other business operations, which are grouped under the Technology and Services segment. This segment’s operations have a shared global market and represent the cutting edge of technology products and services in their industry. These businesses are extremely profitable in their industries and generate positive cash flow. In 2012, the Revenio Group’s net sales totaled EUR 25.4 million, with its operating margin standing at 19.4%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki.

For additional information, please contact President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 olli-pekka.salovaara@revenio.fi www.reveniogroup.fi

See more at:

http://globenewswire.com/news-release/2013/12/04/594371/0/en/Revenio-Group-Corporation-REVENIO-BUYING-MAJORITY-OF-OSCARE-MEDICAL.html#sthash.rLwtOsl0.dpuf

Oscare Medical announces CE mark for its osteoporosis screening device

Oscare Medical has acquired a certificate of conformity with EC directive 93/42/EEC for its product for osteoporosis screening. The CE marking allows the product to be sold in Finland and 24 other EU Member States.

Oscare Medical’s OsCare Sono™ osteoporosis screening device is based on Finnish research. This small, mobile device allows the cost-effective screening of large populations and helps reduce the incidence of minor and avoidable, osteoporosis-related fractures. The measurement is taken from the wrist and is quick, painless and free of ionizing radiation. Osteoporosis is a worldwide and growing problem. In 2010, 22 million women and 5.5 million men were estimated to have osteoporosis in the EU. Often, the condition is diagnosed and treatment begun too late.

A small gallery

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

  • Nulla consequat massa quis enim.
  • Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.
  • In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.
  • Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi.

Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim.

Read more

We have launched our new website!


Welcome to the new Oscare Medical website!

This website has been developed to better serve our customers. The site is developed continuously and new material will be added regularly.

Oscare Medical will be happy to hear your feedback and ideas on how to make www.oscaremedical.com even better.

Please feel free to send us your comments to info@oscaremedical.fi.

Thank you for visiting!